Trending Topic

Motor neuron synapses with muscle fiber via electrical impulse transmission and neurotransmitter release, forming neuromuscular junctions , motor neuron, neuroscience
15 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a terminal condition with a typical life expectancy of 2–5 years from symptom onset. […]

Search Results

Showing Results for multiple sclerosis

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode of Visionary Voices, Dr Anthony Caggiano, Chief Medical Officer at Cognition Therapeutics, joins us to explore how biomarkers are transforming our understanding of Alzheimer’s disease, from diagnosis and disease progression to drug development and the future of clinical care.

Mark CompleteCompleted
BookmarkBookmarked

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a ...

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Mark CompleteCompleted
BookmarkBookmarked

 "this is a field where rigorous science can rapidly change lives"   Dr Bardia Nourbakhsh, Associate Professor of Neurology, Johns Hopkins University, Baltimore, MD, USA, is a rising star whose work bridges rigorous clinical neurological research with compassionate, patient-centred care. ...

Mark CompleteCompleted
BookmarkBookmarked

Multiple sclerosis (MS) is a chronic neurological condition that often presents with vague or intermittent symptoms, making early recognition particularly challenging in primary care. As diagnostic delays can significantly impact long-term outcomes, timely identification and referral are critical. In alignment ...

12 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT FOCUS
Prof. Xavier Montalban

Join an expert as they discuss MS pathophysiology and the potential of BTK inhibitors to delay progression.

Mark CompleteCompleted
BookmarkBookmarked
Pavel Burko, Ilias Miltiadis, Mahsa Alavi

Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in ...

Mark CompleteCompleted
BookmarkBookmarked

touchNEUROLOGY is delighted to congratulate Dr Amit Bar-Or of Penn Medicine on receiving the 2025 John Dystel Prize for Multiple Sclerosis Research, jointly awarded by the National Multiple Sclerosis Society (NMMS) and the American Academy of Neurology (AAN). This honour recognizes his groundbreaking work in neuroimmunology, precision medicine, and biomarker research in multiple sclerosis (MS).

Mark CompleteCompleted
BookmarkBookmarked

Over the past two decades, the understanding and management of multiple sclerosis (MS) have advanced dramatically, reshaping long-held views of the disease. MS is now increasingly seen as a continuous spectrum rather than a condition with distinct phases, with evidence showing it can begin silently, even before clinical symptoms emerge. Technological and diagnostic innovations have enabled the detection of early brain changes and biomarkers, opening doors to earlier diagnosis and intervention. New diagnostic criteria allow MS to be identified without a clinical event, and studies on disease-modifying therapies (DMTs) support the benefits of early treatment. A major shift in treatment strategy is also underway, emphasizing early, aggressive approaches and therapies that target progression rather than just relapses, which are no longer seen as the main driver of long-term disability. A pivotal development in MS research is the confirmation of Epstein–Barr virus (EBV) as a fundamental trigger of the disease, with new evidence pointing to specific viral protein regions as higher-risk factors. Despite these strides, MS research remains a dynamic and evolving field, with much still to be uncovered beneath the surface.

Mark CompleteCompleted
BookmarkBookmarked

The 2025 Annual Meeting of the American Academy of Neurology in San Diego brought together over 14,500 neurology professionals from 110 countries and all 50 US states, alongside more than 300 exhibiting companies. It was a week filled with inspiring science, learning, and global collaboration—all in support of advancing brain health for all. Among the many highlights were the late-breaking abstracts, showcasing some of the most exciting developments in neurology. From this impressive selection, we’ve chosen five standout presentations that reflect the innovation and momentum seen throughout the meeting.

Mark CompleteCompleted
BookmarkBookmarked

In this Q&A, Herbert Temmes shares why prevention is such a crucial and timely topic, how the MS community can be more involved in shaping decisions, and what outcomes he hopes the conference will deliver for years to come.

50 mins
Sponsored Content

Sanofi at ECTRIMS 2024. Join MS experts as they examine disability accumulation through the lens of personalised care, biomarkers, and clinical trial design. Hear their perspectives on the complexities of balancing improved relapse management with the ongoing challenge of disability accumulation.

58 mins
Sponsored Content

Sanofi at EAN 2024. Hear from the experts about our evolving understanding of multiple sclerosis pathophysiology and the role of smoldering neuroinflammation, with a closer look at microglia and BTK.

78 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Spain, Finland, Denmark and Italy

Sanofi at AAN 2024. Join MS experts as they examine the role of smoldering neuroinflammation and its underlying biology, with a closer look at microglia and BTK.

56 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Spain, Finland, Denmark and Italy

Sanofi at ECTRIMS 2023. Explore smoldering neuroinflammation, which results in physical and cognitive disability accumulation, and its impact on your patients.

83 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Spain, Finland, Denmark and Italy

Sanofi at AAN 2023. Explore perspectives on MS disability accumulation in the time of highly effective therapies, the smoldering neuroinflammatory pathway, and CNS biomarkers of the future in this Industry Therapeutic Update.

59 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Spain, Finland, Denmark and Italy

Sanofi at EAN 2023. Learn about the drivers of multiple sclerosis disability accumulation, the unique role of smoldering neuroinflammation, and the role of “big data” in central nervous system biomarkers of the future.

Load More...
Close Popup